Sangamo maintained by JMP at market outperform

Sangamo Biosciences Inc. was maintained by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $8. Ahead of the International Conference on the Mechanisms and Treatment of Neuropathic Pain in early November, where preclinical data is expected on its zinc-finger protein activator of VEGF-A in the treatment of diabetic neuropathy, JMP is hosting a conference call with doctors and researchers in the field. Sangamo shares Thursday were up $0.07, or 1.52%, at $4.58 on volume of 30,300 shares versus the three-month running average of 46,972.3 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.